

Bruce E Strober

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6412284/publications.pdf>

Version: 2024-02-01

187
papers

13,344
citations

26630

56
h-index

23533

111
g-index

191
all docs

191
docs citations

191
times ranked

8820
citing authors

#	ARTICLE	IF	CITATIONS
1	The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas™ Psoriasis Registry. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 71-78.	0.7	9
2	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	3.0	30
3	Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2022, 158, 142.	4.1	8
4	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	2.4	11
5	Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. <i>Dermatology and Therapy</i> , 2022, 12, 381-393.	3.0	13
6	Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naïve Patients with Psoriasis in a US Real-World Setting. <i>Dermatology and Therapy</i> , 2022, 12, 1351-1365.	3.0	2
7	Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). <i>British Journal of Dermatology</i> , 2022, 187, 866-877.	1.5	17
8	Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: A single-institution retrospective chart review. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 726-728.	1.2	1
9	Joint AAD/NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 432-470.	1.2	135
10	Phosphodiesterase-4 and Janus Kinase Inhibitors. , 2021, , 199-208.e3.		0
11	Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 12-15.	0.7	1
12	Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2021, 32, 302-309.	2.2	11
13	Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021, 11, 253-263.	3.0	3
14	How to Best Define Psoriasis Severity: A New Consensus Statement From the International Psoriasis Council. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 6-7.	0.7	0
15	Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 93-98.	0.7	2
16	Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry. <i>Dermatologic Therapy</i> , 2021, 34, e14808.	1.7	26
17	Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. <i>Dermatology and Therapy</i> , 2021, 11, 529-541.	3.0	36
18	POS1032...EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 788-789.	0.9	0

#	ARTICLE	IF	CITATIONS
19	The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. <i>Dermatology and Therapy</i> , 2021, 11, 1079-1083.	3.0	4
20	A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. <i>Dermatology and Therapy</i> , 2021, 11, 1851-1860.	3.0	8
21	Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. <i>British Journal of Dermatology</i> , 2021, 185, 840-842.	1.5	3
22	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate to severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.5	36
23	Getting personal about skin: Realizing precision medicine in dermatology. <i>Dermatological Reviews</i> , 2021, 2, 289-295.	0.5	3
24	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 2219-2229.	27.0	93
25	US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 31, 333-341.	2.2	23
26	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	1.2	120
27	Hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1045-1058.	1.2	202
28	Hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1061-1082.	1.2	69
29	Joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 161-201.	1.2	129
30	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 1484-1487.	1.5	2
31	Letter from the New Editor in Chief. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 81-81.	0.7	0
32	The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1533-1535.	1.2	2
33	PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 131-138.	1.2	9
34	Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 96-103.	1.2	47
35	Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-9.	2.2	1
36	Joint American Academy of Dermatology and National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1445-1486.	1.2	184

#	ARTICLE	IF	CITATIONS
37	Comparative Effectiveness Studies for Psoriasis—The Methods Matter. <i>JAMA Dermatology</i> , 2020, 156, 253.	4.1	1
38	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltimMa [®] 1 and UltimMa [®] 2 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2830-2838.	2.4	46
39	Treatment of refractory dissecting cellulitis of the scalp with guselkumab: Case report. <i>Journal of Dermatology & Dermatologic Surgery</i> , 2020, 24, 52.	0.2	3
40	Joint American Academy of Dermatology—National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 775-804.	1.2	105
41	Apremilast mechanism of efficacy in systemic-naïve patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. <i>Journal of Dermatological Science</i> , 2019, 96, 126-133.	1.9	9
42	Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 886-892.	2.4	34
43	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 699-709.	6.7	5
44	Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. <i>BMJ Open</i> , 2019, 9, e027535.	1.9	44
45	Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. <i>Drug Safety</i> , 2019, 42, 751-768.	3.2	93
46	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	1.2	542
47	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1073-1113.	1.2	281
48	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 76-85.	1.5	23
49	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019, 180, 67-75.	1.5	33
50	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18.	3.0	63
51	Methotrexate treatment of generalized granuloma annulare: a retrospective case series. <i>Journal of Dermatological Treatment</i> , 2018, 29, 720-724.	2.2	10
52	Janus Kinase Inhibitors. , 2018, , 187-198.		2
53	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 323-332.	1.2	73
54	Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 333-335.	1.2	3

#	ARTICLE	IF	CITATIONS
55	No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2018, 178, e105-e107.	1.5	16
56	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 70-80.	1.2	78
57	Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 587-596.	1.6	13
58	Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. <i>British Journal of Dermatology</i> , 2018, 179, 1205-1207.	1.5	69
59	Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2126-2133.	2.4	12
60	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018, 392, 650-661.	13.7	457
61	Core Outcome Sets for Psoriasis Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1135.	4.1	0
62	Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 655-661.	1.2	28
63	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. <i>Journal of Dermatological Treatment</i> , 2017, 28, 492-499.	2.2	44
64	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1537-1551.	1.5	43
65	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1093-1102.	1.2	110
66	Clinical trials: Kids are not just little people. <i>Clinics in Dermatology</i> , 2017, 35, 583-593.	1.6	9
67	Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. <i>Value in Health</i> , 2017, 20, 1174-1179.	0.3	8
68	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1562-1574.	1.5	68
69	How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 569-572.	1.2	5
70	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 432-440.e17.	1.2	111
71	Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 73-80.	0.7	1
72	Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. <i>Journal of Drugs in Dermatology</i> , 2017, 16, 801-808.	0.8	38

#	ARTICLE	IF	CITATIONS
73	Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 167-174.	0.7	1
74	Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. <i>International Journal of Dermatology</i> , 2016, 55, 401-407.	1.0	34
75	Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. <i>International Journal of Dermatology</i> , 2016, 55, e147-55.	1.0	14
76	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 77-82.e7.	1.2	96
77	Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. <i>British Journal of Dermatology</i> , 2016, 174, 212-215.	1.5	6
78	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 897-905.	1.2	38
79	Psoriasis in adults and children: Kids are not just little people. <i>Clinics in Dermatology</i> , 2016, 34, 717-723.	1.6	10
80	060 Integrated safety of ixekizumab in patients with moderate-to-severe psoriasis: results from a pooled analysis of 7 clinical trials. <i>Journal of Investigative Dermatology</i> , 2016, 136, S170.	0.7	0
81	Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. <i>Pediatric Dermatology</i> , 2016, 33, 142-149.	0.9	29
82	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and) Tj ETQq0 0 0 rgBT / Overlock 103Tf 50 377		
83	Anti-interleukin-17 treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 311-315.	2.2	12
84	New Therapies for Psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2016, 35, S71-S73.	1.6	3
85	Why Biologic Therapies Sometimes Lose Efficacy. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2016, 35, S78-S80.	1.6	11
86	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S5-S29.	0.1	2
87	Interleukin-23 inhibition for the treatment of psoriasis: the next frontier for high-efficacy biologic therapy. <i>British Journal of Dermatology</i> , 2015, 173, 887-888.	1.5	0
88	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 436-439.e1.	1.2	49
89	Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report. <i>JAAD Case Reports</i> , 2015, 1, 3-4.	0.8	20
90	Interferon beta-1a-induced morphea. <i>JAAD Case Reports</i> , 2015, 1, 15-17.	0.8	8

#	ARTICLE	IF	CITATIONS
91	Measurement Properties of the patient-reported Psoriasis Symptom inventory daily diary in patients with moderate to severe Plaque Psoriasis. <i>Value in Health</i> , 2015, 18, A183.	0.3	0
92	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	27.0	656
93	Current and Future Oral Systemic Therapies for Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 91-109.	1.7	26
94	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, S4-S26.	0.1	1
95	Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data. <i>Value in Health</i> , 2014, 17, A288.	0.3	1
96	Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1701-1706.	2.4	13
97	The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. <i>International Journal of Dermatology</i> , 2014, 53, 714-722.	1.0	53
98	Methotrexate-Induced Liver Toxicity. <i>JAMA Dermatology</i> , 2014, 150, 862.	4.1	7
99	Similar Names for Similar Biologics. <i>BioDrugs</i> , 2014, 28, 439-444.	4.6	14
100	Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities. <i>American Journal of Medicine</i> , 2014, 127, 1148-1153.	1.5	59
101	Understanding Therapeutic Pathways and Comorbidities in Psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S20-S23.	1.6	5
102	Methotrexate and Cyclosporine in Psoriasis Revisited. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S27-S30.	1.6	9
103	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, S5-S22.	0.1	0
104	Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1252-1261.	2.4	56
105	Community differentiation of the cutaneous microbiota in psoriasis. <i>Microbiome</i> , 2013, 1, 31.	11.1	353
106	Treatment of atopic dermatitis in pregnancy. <i>Dermatologic Therapy</i> , 2013, 26, 293-301.	1.7	24
107	Item-Level Psychometric Properties for a New Patient-Reported Psoriasis Symptom Diary. <i>Value in Health</i> , 2013, 16, 1014-1022.	0.3	28
108	Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. <i>British Journal of Dermatology</i> , 2013, 168, 210-212.	1.5	22

#	ARTICLE	IF	CITATIONS
109	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>British Journal of Dermatology</i> , 2013, 168, 844-854.	1.5	350
110	Topical Chemotherapy in Cutaneous T-cell Lymphoma. <i>JAMA Dermatology</i> , 2013, 149, 25.	4.1	147
111	Pharmacovigilance and biosimilars: considerations, needs and challenges. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1039-1047.	3.1	63
112	Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. <i>British Journal of Dermatology</i> , 2013, 169, 992-999.	1.5	84
113	Biologic therapy for psoriasis: early response implies future success. <i>British Journal of Dermatology</i> , 2013, 169, 1178-1179.	1.5	1
114	Management of psoriasis in pregnancy. <i>Dermatologic Therapy</i> , 2013, 26, 285-292.	1.7	17
115	Dose Response and Pharmacokinetics of Tofacitinib (CP690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-8.	2.5	4
116	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2013, 6, S2-S20.	0.1	17
117	A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 304-314.	0.7	157
118	A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012, 167, 649-657.	1.5	116
119	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. <i>British Journal of Dermatology</i> , 2012, 167, 668-677.	1.5	281
120	Ethical considerations when prescribing biologics in dermatology. <i>Clinics in Dermatology</i> , 2012, 30, 492-495.	1.6	4
121	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 731-741.	1.2	101
122	Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 317-322.	1.2	55
123	Methotrexate and psoriasis: Consensus conference. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 689-690.	1.2	1
124	Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIb trial. <i>British Journal of Dermatology</i> , 2012, 167, 1374-1381.	1.5	59
125	Consensus Guidelines for the Management of Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 95.	1.4	148
126	A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. <i>Dermatology and Therapy</i> , 2012, 2, 1.	3.0	18

#	ARTICLE	IF	CITATIONS
127	A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. <i>Dermatology and Therapy</i> , 2012, 2, 2.	3.0	10
128	PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 1210-7.	0.8	63
129	The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 321-337.	6.7	62
130	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 671-681.	1.2	69
131	Methotrexate and psoriasis: Consensus conference. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1179.	1.2	5
132	Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 661-668.	1.5	128
133	Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial. <i>Dermatology</i> , 2011, 222, 36-48.	2.1	20
134	Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 864-71.	7.4	259
135	Successful Treatment of Subacute Lupus Erythematosus With Ustekinumab. <i>Archives of Dermatology</i> , 2011, 147, 896.	1.4	57
136	Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 1349-1358.	1.5	39
137	Evaluation of the cutaneous microbiome in psoriasis. <i>Nature Precedings</i> , 2010, , .	0.1	0
138	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. <i>New England Journal of Medicine</i> , 2010, 362, 118-128.	27.0	773
139	Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 291-299.	1.2	132
140	The Treatment of Moderate-to-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 28-34.	1.6	6
141	Enhancing DNA repair in the skin: A pilot study of low-dose chloroquine and ultraviolet light.. <i>Journal of Clinical Oncology</i> , 2010, 28, 8566-8566.	1.6	0
142	Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. <i>Journal of Drugs in Dermatology</i> , 2010, 9, 928-37.	0.8	69
143	Alefacept for Severe Alopecia Areata. <i>Archives of Dermatology</i> , 2009, 145, 1262-6.	1.4	40
144	Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 824-837.	1.2	289

#	ARTICLE	IF	CITATIONS
145	A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, S1-S46.	1.2	35
146	Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2567-2569.	0.7	2
147	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. <i>British Journal of Dermatology</i> , 2008, 159, 322-330.	1.5	176
148	Tinea versicolor associated with etanercept therapy. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, S99-S100.	1.2	11
149	From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 94-105.	1.2	109
150	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 106-115.	1.2	796
151	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1031-1042.	1.2	383
152	Rethinking eligibility creep. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 165-167.	1.2	2
153	An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. <i>Current Medical Research and Opinion</i> , 2008, 24, 1529-1538.	1.9	115
154	Efalizumab-Associated Guillain-Barré Syndrome. <i>Archives of Dermatology</i> , 2008, 144, 1396-7.	1.4	11
155	Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions. <i>PLoS ONE</i> , 2008, 3, e2719.	2.5	388
156	National Psoriasis Foundation Clinical Consensus on Disease Severity. <i>Archives of Dermatology</i> , 2007, 143, 239-42.	1.4	132
157	Reconsidering liver biopsies during methotrexate therapy. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 893-894.	1.2	10
158	Efalizumab for the treatment of refractory hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 1090-1091.	1.2	23
159	Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. <i>British Journal of Dermatology</i> , 2007, 156, 138-142.	1.5	32
160	Folate with methotrexate: big benefit, questionable cost. <i>British Journal of Dermatology</i> , 2007, 157, 213-213.	1.5	11
161	Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. <i>British Journal of Dermatology</i> , 2007, 157, 649-655.	1.5	273
162	Alefacept for the treatment of psoriasis and other dermatologic diseases. <i>Dermatologic Therapy</i> , 2007, 20, 270-276.	1.7	26

#	ARTICLE	IF	CITATIONS
163	Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. <i>Journal of Dermatological Treatment</i> , 2006, 17, 343-352.	2.2	43
164	A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 40-46.	1.2	50
165	On multiple courses of alefacept. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 916-917.	1.2	1
166	Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris. <i>Archives of Dermatology</i> , 2006, 142, 605-12.	1.4	53
167	Molecular Analysis of Fungal Microbiota in Samples from Healthy Human Skin and Psoriatic Lesions. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2933-2941.	3.9	223
168	Conventional systemic agents for psoriasis. A systematic review. <i>Journal of Rheumatology</i> , 2006, 33, 1442-6.	2.0	55
169	Off-Label Dermatologic Uses of Anti-TNF- α Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 296-302.	1.2	11
170	Off-Label Dermatologic Uses of Anti-TNF- α Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 296-302.	1.2	83
171	Successful Treatment of Plaque Psoriasis With Self-administered Subcutaneous Alefacept. <i>Archives of Dermatology</i> , 2005, 141, 1602.	1.4	4
172	Alefacept in the treatment of psoriatic nail disease: A small case series. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 1101-1102.	1.2	31
173	Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 1082-1084.	1.2	100
174	Folate supplementation during methotrexate therapy for patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 652-659.	1.2	82
175	The treatment of psoriasis with etanercept. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2005, 24, 28-36.	1.6	6
176	Successful Treatment of Psoriasis and Psoriatic Arthritis With Etanercept and Methotrexate in a Patient Newly Unresponsive to Infliximab. <i>Archives of Dermatology</i> , 2004, 140, 366.	1.4	20
177	Toxic epidermal necrolysis-like reaction secondary to colchicine overdose. <i>British Journal of Dermatology</i> , 2004, 150, 581-588.	1.5	29
178	Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P147.	1.2	0
179	Efficacy of etanercept in psoriatic patients previously treated with systemic therapy or phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P147.	1.2	0
180	Alefacept in the treatment of psoriatic nail disease. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P151.	1.2	2

#	ARTICLE	IF	CITATIONS
181	Etanercept for the treatment of psoriasis: combination therapy with other modalities. Journal of Drugs in Dermatology, 2004, 3, 270-2.	0.8	26
182	Cutaneous Bacillus anthracis Infection. New England Journal of Medicine, 2001, 345, 1646-1647.	27.0	3
183	Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis, 2001, 67, 109-10.	0.3	13
184	Functional Interactions between the hBRM/hBRG1 Transcriptional Activators and the pRB Family of Proteins. Molecular and Cellular Biology, 1996, 16, 1576-1583.	2.3	246
185	The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell, 1994, 79, 119-130.	28.9	622
186	Gender Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032210998.	0.7	0
187	Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal of Dermatological Treatment, 0, , 1-9.	2.2	1